A5052789300- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Hemophilia Treatment and Research
- Autoimmune Bullous Skin Diseases
- Urticaria and Related Conditions
- Asthma and respiratory diseases
- Vitamin K Research Studies
- Mast cells and histamine
- Immunodeficiency and Autoimmune Disorders
- Drug-Induced Adverse Reactions
- Respiratory and Cough-Related Research
- Chronic Myeloid Leukemia Treatments
- Pharmaceutical studies and practices
- Platelet Disorders and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- PI3K/AKT/mTOR signaling in cancer
- Education and Technology Integration
- Blood groups and transfusion
- Health Systems, Economic Evaluations, Quality of Life
- Medical Imaging Techniques and Applications
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- Cystic Fibrosis Research Advances
- Pediatric health and respiratory diseases
- Inflammation biomarkers and pathways
- Microscopic Colitis
University of Alabama at Birmingham
2010-2025
St. Vincent's Birmingham
2023
Antea Group (France)
2023
Institute of Electrical and Electronics Engineers
2013-2023
University of Colorado Colorado Springs
2023
Nationwide Children's Hospital
2023
Allergy, Asthma and Clinical Research Center
2017-2022
Clinical Research Management
2017-2021
Academic Pediatric Association
2021
St. Luke's Hospital
2021
Current treatments for long-term prophylaxis in hereditary angioedema have limitations.To assess the efficacy of lanadelumab, a fully human monoclonal antibody that selectively inhibits active plasma kallikrein, preventing attacks.Phase 3, randomized, double-blind, parallel-group, placebo-controlled trial conducted at 41 sites Canada, Europe, Jordan, and United States. Patients were randomized between March 2016, September 9, 2016; last day follow-up was April 13, 2017. Randomization 2:1...
Hereditary angioedema is a disabling, potentially fatal condition caused by deficiency (type I) or dysfunction II) of the C1 inhibitor protein. In phase 2 trial, use CSL830, nanofiltered preparation that suitable for subcutaneous injection, resulted in functional levels activity would be expected to provide effective prophylaxis attacks.We conducted an international, prospective, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 3 trial evaluate efficacy and safety...
BackgroundBerotralstat (BCX7353) is an oral, once-daily inhibitor of plasma kallikrein in development for the prophylaxis hereditary angioedema (HAE) attacks.ObjectiveOur aim was to determine efficacy, safety, and tolerability berotralstat patients with HAE over a 24-week treatment period (the phase 3 APeX-2 trial).MethodsAPeX-2 double-blind, parallel-group study that randomized at 40 sites 11 countries 1:1:1 receive dose 110 mg or 150 placebo (Clinicaltrials.gov identifier NCT03485911)....
Hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) impairs health-related quality of life (HRQoL).The objective this study was to assess HRQoL outcomes in patients self-administering subcutaneous C1-INH (C1-INH[SC]; HAEGARDA) for routine prevention HAE attacks.Post hoc analysis data from the placebo-controlled, crossover phase III COMPACT (Clinical Studies Optimal Management Preventing Angioedema Low-Volume Subcutaneous C1-Inhibitor Replacement Therapy). Ninety C1-INH-HAE were...
<h3>Background</h3> For the prevention of attacks hereditary angioedema (HAE), efficacy and safety subcutaneous human C1-esterase inhibitor (C1-INH[SC]; HAEGARDA, CSL Behring) was established in 16-week Clinical Study for Optimal Management Preventing Angioedema with Low-Volume Subcutaneous C1-Inhibitor Replacement Therapy (COMPACT). <h3>Objective</h3> To assess long-term safety, occurrence attacks, use rescue medication C1-INH(SC). <h3>Methods</h3> Open-label, randomized, parallel-arm...
All patients with hereditary angioedema (HAE) must have access to on-demand therapy treat attacks and may benefit from prophylactic reduce the attack frequency.Treatment decisions should be individualized, based on patient preferences needs.One method for facilitating individualized is shared decision-making (SDM), a widely used methodology making treatment among multiple therapeutic options.We propose three-phase "3D" model (Discover, Discuss, Decide) SDM in HAE.The Discover phase focuses...
Abstract Background Long-term prophylaxis with subcutaneous C1-inhibitor (C1-INH[SC]; HAEGARDA, CSL Behring) in patients hereditary angioedema (HAE) due to C1-INH deficiency (C1-INH-HAE) was evaluated an open-label extension follow-up study the international, double-blind, placebo-controlled COMPACT study. The current analysis patient-reported health-related quality of life (HRQoL) data from 126 randomized treatment C1-INH(SC) 40 IU/kg (n = 63) or 60 twice weekly for 52 weeks. HRQoL at...
Hereditary angioedema (HAE) is a complex disorder with wide array of treatment options. Shared decision-making (SDM) should be used to ensure that patients are choosing their best option. The goal was develop and psychometrically test brief instrument for assessing the patient's perspective SDM process during his or her clinical encounters an HAE specialist/allergist.
BackgroundBerotralstat is a first-line, once-daily oral plasma kallikrein inhibitor approved for prophylaxis of hereditary angioedema (HAE) attacks in patients 12 years or older.ObjectiveThis analysis examined the safety and effectiveness long-term with berotralstat.MethodsAPeX-2 was phase 3, parallel-group, multicenter trial HAE caused by C1-inhibitor deficiency (NCT03485911). Part 1 randomized, double-blind, placebo-controlled evaluation 150 110 mg berotralstat over 24 weeks. In part 2,...
In the article "Management of Asthma" by Section on Allergy and Immunology American Academy Pediatrics (Pediatrics 68:874-879, 1981) corrections should be made p 876, fourth paragraph, as follows: Line 15, sentence read: After loading dose, a constant maintenance infusion aminophylline 0.85 mg/kg/hr for children 1 to 9 years old, 0.65 16 0.45 adults usually will maintain serum concentrations approximately 10 µg/ml. 23, Average theophylline dosage infants less than year old relates age can...
Background: Hereditary angioedema (HAE) is a rare genetic disorder clinically characterized by recurrent attacks of subcutaneous and mucosal swelling. Attenuated androgens have been prophylactic treatment option to reduce the frequency HAE for > 4 decades. However, advent effective on-demand treatments highly effective, more tolerable, long-term therapies has led decline in use attenuated management regions where newer are available. A consensus about best approach discontinuing or tapering...